-transparent.png){kind=logo}
The pharmacokinetics of cefotaxime and its main metabolite des-acetyl-cefotaxime were studied after a single 1000 mg intravenous dose in 8 patients with end stage renal disease during peritoneal dialysis. Pharmacokinetic parameters were determined by iterative non-linear least squares regression analysis of plasma and dialysis fluid drug concentration curves. Biological half-life of cefotaxime ranged from 2.3 to 8.2 hours and total plasma clearance from 11 to 103 ml/min. (0.11 to 1.7 ml/min/kg b.wt). Only 1.4% to 4.2% of the intravenous dose of cefotaxime was distributed to the dialysis fluid. We conclude that the dosage of cefotaxime to uraemic patients adjusted to the renal function needs no further adjustment during peritoneal dialysis.
S Overgaard, and
N Løkkegaard, and
S Scrøder, and
S Fugleberg, and
F Nielsen-Kudsk
July 1986,
Antimicrobial agents and chemotherapy,
S Overgaard, and
N Løkkegaard, and
S Scrøder, and
S Fugleberg, and
F Nielsen-Kudsk
February 1981,
Antimicrobial agents and chemotherapy,
S Overgaard, and
N Løkkegaard, and
S Scrøder, and
S Fugleberg, and
F Nielsen-Kudsk
October 1996,
The Annals of pharmacotherapy,
S Overgaard, and
N Løkkegaard, and
S Scrøder, and
S Fugleberg, and
F Nielsen-Kudsk
March 1992,
The Annals of pharmacotherapy,
S Overgaard, and
N Løkkegaard, and
S Scrøder, and
S Fugleberg, and
F Nielsen-Kudsk
September 1985,
Clinical pharmacology and therapeutics,
S Overgaard, and
N Løkkegaard, and
S Scrøder, and
S Fugleberg, and
F Nielsen-Kudsk
January 1986,
European journal of clinical pharmacology,
S Overgaard, and
N Løkkegaard, and
S Scrøder, and
S Fugleberg, and
F Nielsen-Kudsk
September 1984,
The Journal of antimicrobial chemotherapy,
S Overgaard, and
N Løkkegaard, and
S Scrøder, and
S Fugleberg, and
F Nielsen-Kudsk
January 1990,
Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis,
S Overgaard, and
N Løkkegaard, and
S Scrøder, and
S Fugleberg, and
F Nielsen-Kudsk
January 1995,
Diagnostic microbiology and infectious disease,
S Overgaard, and
N Løkkegaard, and
S Scrøder, and
S Fugleberg, and
F Nielsen-Kudsk
October 1996,
Clinical pharmacokinetics,
